Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
The article compares Recursion Pharmaceuticals (RXRX) and Schrödinger (SDGR) as digital drug-discovery platforms. Recursion reported FY2025 revenue of about $74.7M (+26.9%) and a net loss of about $644.8M, with negative free cash flow of about $378.3M and a debt-to-equity ratio near 0.1x. Schrödinger posted FY2025 revenue of about $255.9M (+23.3%), net loss about $103.3M, and free cash flow about $12.5M.
How this was made
The 30-second read
Why it matters
It does not announce a new deal, trial result, regulatory action, or earnings print; it instead contrasts business models and highlights risk/financial metrics already presented in the narrative.
Market read
Useful for positioning (platform/software vs clinical-stage risk), but not a fresh tradable catalyst.
What to watch
Key missing items for trading: current valuation multiples vs peers, cash runway details, contract churn/renewal rates, and whether the stated 2026 opex/contract expectations were newly disclosed or already known.
Background
The article compares Recursion (AI/data-driven biotech platform) versus Schrödinger (computational chemistry/physics software plus drug programs) as a 2026 investment choice.
Ticker impact
Article frames Recursion as clinical-stage with no approved products, emphasizing partner concentration risk and large ongoing losses/FCF burn.
Bias toward volatility on any partner/clinical execution headlines; absent new catalysts, likely limited upside follow-through.
The piece is an opinion-style comparison but highlights concrete risk drivers (no approved products, partner concentration, negative FCF, net loss).
Article positions Schrödinger as more software-driven, citing FY25 revenue growth, improved losses, positive FY25 FCF, and expected opex decline in 2026.
Potentially steadier downside than RXRX if contract value and opex guidance are credible; still sensitive to drug-program setbacks.
The article provides specific operating metrics (FY25 revenue/net loss/FCF, Q1 contract value growth, expected opex decline) but does not report a fresh event like earnings or guidance release.
Market effects
Reinforces the market’s bifurcation between platform/software-enabled discovery firms and clinical-stage biotechs with no approved products.
None specific; US-listed healthcare/software names only.
None specific; discussion is company fundamentals rather than cross-border policy or supply shocks.
Counterpoint
The article may underweight the possibility that RXRX’s platform monetization improves faster than expected or that SDGR’s drug programs could create upside beyond software stability.
Key entities
- companyRecursion Pharmaceuticals
Clinical-stage platform company with no approved products; highlighted partner concentration and large net losses/negative free cash flow.
- companySchrödinger
Software platform company with improving loss profile and positive free cash flow; highlighted contract value growth and expected operating expense decline in 2026.
